{"analyses":[{"ciLowerLimit":"0.64","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.96","estimateComment":"Unadjusted HR from Cox model with treatment as the only cofactor.","groupDescription":"Type 1 (alpha) error was controlled for the analyses of both PFS and OS in order to maintain an overall two-sided alpha level of 0.05 using a statistical gatekeeping and alpha spending scheme. The unconditional statistical power of the final OS analysis was 93%.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0195","pValueComment":"The predefined alpha for the final analysis of OS is 0.0498 for the unadjusted log-rank test.","paramType":"Hazard Ratio (HR)","paramValue":"0.78","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.75","upperLimit":"16.03","value":"13.86"},{"groupId":"OG001","lowerLimit":"9.95","upperLimit":"12.52","value":"11.01"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"359"},{"groupId":"OG001","value":"180"}],"units":"Participants"}],"description":"OS is the duration from enrollment to death. For patients who are alive, OS is censored at the last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"pemetrexed and cisplatin followed by maintenance pemetrexed plus best supportive care","id":"OG000","title":"Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed"},{"description":"pemetrexed and cisplatin followed by placebo plus best supportive care","id":"OG001","title":"Pemetrexed + Cisplatin Followed by Placebo"}],"paramType":"MEDIAN","populationDescription":"All randomized participants. In the Pemetrexed maintenance arm 103 (28.7%) participants were censored and in the Placebo maintenance arm 39 (21.7%) participants were censored.","reportingStatus":"POSTED","timeFrame":"Date of randomization to the date of death from any cause up to 39.5 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}